ATE442861T1 - Gegen antikörper gerichtete photodynamische therapie - Google Patents
Gegen antikörper gerichtete photodynamische therapieInfo
- Publication number
- ATE442861T1 ATE442861T1 AT04718503T AT04718503T ATE442861T1 AT E442861 T1 ATE442861 T1 AT E442861T1 AT 04718503 T AT04718503 T AT 04718503T AT 04718503 T AT04718503 T AT 04718503T AT E442861 T1 ATE442861 T1 AT E442861T1
- Authority
- AT
- Austria
- Prior art keywords
- photodynamic therapy
- directed against
- therapy directed
- against antibodies
- photosensitizer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45265503P | 2003-03-07 | 2003-03-07 | |
| PCT/US2004/006985 WO2004080284A2 (en) | 2003-03-07 | 2004-03-08 | Antibody-targeted photodynamic therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE442861T1 true ATE442861T1 (de) | 2009-10-15 |
Family
ID=32990667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04718503T ATE442861T1 (de) | 2003-03-07 | 2004-03-08 | Gegen antikörper gerichtete photodynamische therapie |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20060231107A1 (de) |
| EP (1) | EP1605847B1 (de) |
| AT (1) | ATE442861T1 (de) |
| CA (1) | CA2530166A1 (de) |
| DE (1) | DE602004023183D1 (de) |
| WO (1) | WO2004080284A2 (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005117987A1 (en) * | 2004-06-01 | 2005-12-15 | Glazier Alan N | Antibody conjugates targeting to ocular proteins |
| GB0520436D0 (en) | 2005-10-07 | 2005-11-16 | Photobiotics Ltd | Biological materials and uses thereof |
| US7465312B2 (en) * | 2006-05-02 | 2008-12-16 | Green Medical, Inc. | Systems and methods for treating superficial venous malformations like spider veins |
| WO2007130465A2 (en) * | 2006-05-02 | 2007-11-15 | Green Medical, Inc. | Systems and methods for treating superficial venous malformations like spider veins |
| US8034091B2 (en) * | 2007-06-08 | 2011-10-11 | Laserix Sarl | Method for the ablation of cartilage tissue in a knee joint using indocyanine |
| MX337922B (es) * | 2008-12-16 | 2016-03-28 | Valeant Pharmaceuticals Int | Combinacion de terapia fotodinamica y agentes anti-vegf en el tratamiento de neovasculatura coroidal indeseable. |
| JP5808107B2 (ja) * | 2008-12-17 | 2015-11-10 | 学校法人慶應義塾 | 細胞特異的能動集積性を有する光線力学療法剤 |
| AU2011210536A1 (en) | 2010-02-01 | 2012-09-13 | Conversion Energy Enterprises Inc. | Methods and devices for crosslinking of corneal collagen and for treatment of disorders of the eye |
| US8524239B2 (en) * | 2010-07-09 | 2013-09-03 | The United States of America as represented by the Secrectary, Department of Health and Human Services | Photosensitizing antibody-fluorophore conjugates |
| SG187012A1 (en) * | 2010-07-19 | 2013-02-28 | Hoffmann La Roche | Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer |
| WO2012037355A2 (en) * | 2010-09-16 | 2012-03-22 | Case Western Reserve University | Photodynamic therapy system, device and associated method of treatment |
| CN103739710B (zh) * | 2014-01-26 | 2015-12-09 | 中国人民解放军军事医学科学院基础医学研究所 | 一种抗vegf抗体及其应用 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| US10830678B2 (en) | 2014-08-08 | 2020-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Photo-controlled removal of targets in vitro and in vivo |
| CN121270700A (zh) | 2015-08-07 | 2026-01-06 | 美国政府(由卫生和人类服务部的部长所代表) | 用于治疗癌症的针对抑制细胞的近红外光免疫疗法(nir-pit) |
| ES2889904T3 (es) | 2015-08-18 | 2022-01-14 | Rakuten Medical Inc | Conjugados de colorante de ftalocianina y su almacenamiento |
| US11154620B2 (en) | 2015-08-18 | 2021-10-26 | Rakuten Medical, Inc. | Compositions, combinations and related methods for photoimmunotherapy |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| EP3758737A4 (de) | 2018-03-02 | 2022-10-12 | Kodiak Sciences Inc. | Il-6-antikörper und fusionskonstrukte und konjugate davon |
| EP3886946A1 (de) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Vorrichtungen und verfahren zur präzisionsdosisverabreichung |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4684521A (en) * | 1982-12-08 | 1987-08-04 | Frederic A. Bourke, Jr. | Method and system for externally treating the blood |
| US4506680A (en) * | 1983-03-17 | 1985-03-26 | Medtronic, Inc. | Drug dispensing body implantable lead |
| US4606118A (en) * | 1985-02-27 | 1986-08-19 | Medtronic, Inc. | Method of making a drug dispensing body |
| US4577642A (en) * | 1985-02-27 | 1986-03-25 | Medtronic, Inc. | Drug dispensing body implantable lead employing molecular sieves and methods of fabrication |
| US5093349A (en) * | 1988-07-20 | 1992-03-03 | Health Research Inc. | Photosensitizing agents |
| US5002962A (en) * | 1988-07-20 | 1991-03-26 | Health Research, Inc. | Photosensitizing agents |
| US5177073A (en) * | 1988-09-30 | 1993-01-05 | Baylor Research Institute | Therapeutic compositions derived from photoactive compounds |
| US5238940A (en) * | 1990-03-22 | 1993-08-24 | Quadra Logic Technologies Inc. | Compositions for photodynamic therapy |
| US5053423A (en) * | 1990-03-22 | 1991-10-01 | Quadra Logic Technologies Inc. | Compositions for photodynamic therapy |
| US5589563A (en) * | 1992-04-24 | 1996-12-31 | The Polymer Technology Group | Surface-modifying endgroups for biomedical polymers |
| US5652138A (en) | 1992-09-30 | 1997-07-29 | The Scripps Research Institute | Human neutralizing monoclonal antibodies to human immunodeficiency virus |
| US5405957A (en) * | 1992-10-30 | 1995-04-11 | The University Of British Columbia | Wavelength-specific photosensitive compounds and expanded porphyrin-like compounds and methods of use |
| US5454794A (en) * | 1993-10-15 | 1995-10-03 | Pdt Systems, Inc. | Steerable light diffusing catheter |
| US5798349A (en) * | 1994-03-14 | 1998-08-25 | The General Hospital Corporation | Use of green porphyrins to treat neovasculature in the eye |
| US5707986A (en) * | 1994-03-14 | 1998-01-13 | Miller; Joan W. | Angiographic method using green porphyrins in primate eyes |
| CA2215978A1 (en) * | 1995-04-04 | 1996-10-10 | Wound Healing Of Oklahoma | Cancer treatment by photodynamic therapy, in combination with an immunoadjuvant |
| RU2066552C1 (ru) * | 1996-02-12 | 1996-09-20 | Товарищество с ограниченной ответственностью "Био Прогресс" | Композиция для фотодинамического повреждения клеток-мишеней и способ фотодинамического повреждения клеток-мишеней |
| US5756541A (en) * | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
| NZ331977A (en) * | 1996-03-26 | 2000-07-28 | Pharmacyclics Inc | Texaphyrin in photodynamic therapy of pigment-related lesions |
| US6416960B1 (en) * | 1996-08-08 | 2002-07-09 | Prolume, Ltd. | Detection and visualization of neoplastic tissues and other tissues |
| US5877263A (en) * | 1996-11-25 | 1999-03-02 | Meadox Medicals, Inc. | Process for preparing polymer coatings grafted with polyethylene oxide chains containing covalently bonded bio-active agents |
| US6043237A (en) * | 1996-12-10 | 2000-03-28 | Qlt Phototherapeutics, Inc. | Use of photodynamic therapy for prevention of secondary cataracts |
| FR2765243B1 (fr) | 1997-06-30 | 1999-07-30 | Usinor | Acier inoxydable austenoferritique a tres bas nickel et presentant un fort allongement en traction |
| GB9818731D0 (en) * | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
| US6364907B1 (en) * | 1998-10-09 | 2002-04-02 | Qlt Inc. | Method to prevent xenograft transplant rejection |
| ATE335513T1 (de) * | 1998-10-16 | 2006-09-15 | Gen Hospital Corp | Photosensitizer-konjugate zur zielrichtung von intrazellulare pathogene |
| US6344050B1 (en) * | 1998-12-21 | 2002-02-05 | Light Sciences Corporation | Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue |
| US6602274B1 (en) * | 1999-01-15 | 2003-08-05 | Light Sciences Corporation | Targeted transcutaneous cancer therapy |
| US6342219B1 (en) * | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody compositions for selectively inhibiting VEGF |
| US6443976B1 (en) * | 1999-11-30 | 2002-09-03 | Akorn, Inc. | Methods for treating conditions and illnesses associated with abnormal vasculature |
| US6319273B1 (en) * | 1999-12-16 | 2001-11-20 | Light Sciences Corporation | Illuminating device for treating eye disease |
| US20020049247A1 (en) * | 2000-01-12 | 2002-04-25 | Chen James C. | Novel treatment for eye disease |
| US6180087B1 (en) * | 2000-01-18 | 2001-01-30 | Mallinckrodt Inc. | Tunable indocyanine dyes for biomedical applications |
| WO2001058240A2 (en) * | 2000-02-10 | 2001-08-16 | Massachusetts Eye And Ear Infirmary | Photodynamic therapy for treating conditions of the eye |
| AU2001280754A1 (en) * | 2000-07-24 | 2002-02-05 | Research Development Foundation | Enhancement of photodynamic therapy by anti-angiogenic treatment |
| WO2002058730A2 (en) * | 2000-11-01 | 2002-08-01 | Allergan, Inc. | Compositions for treatment of ocular neovascularization |
| CA2437563C (en) * | 2001-02-06 | 2010-03-23 | Qlt Inc. | Photodynamic therapy of occult age-related macular degeneration |
| US7753943B2 (en) * | 2001-02-06 | 2010-07-13 | Qlt Inc. | Reduced fluence rate PDT |
| CA2445898A1 (en) * | 2001-05-01 | 2002-12-19 | The General Hospital Corporation | Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies |
| JP2005511576A (ja) * | 2001-11-09 | 2005-04-28 | アイテック・ファーマシューティカルズ | 眼球血管新生病を治療する方法 |
| US6968234B2 (en) * | 2002-04-25 | 2005-11-22 | Medtronic, Inc. | Implantable medical device having biologically active polymeric casing |
-
2004
- 2004-03-08 AT AT04718503T patent/ATE442861T1/de not_active IP Right Cessation
- 2004-03-08 CA CA002530166A patent/CA2530166A1/en not_active Abandoned
- 2004-03-08 WO PCT/US2004/006985 patent/WO2004080284A2/en not_active Ceased
- 2004-03-08 EP EP04718503A patent/EP1605847B1/de not_active Expired - Lifetime
- 2004-03-08 US US10/548,183 patent/US20060231107A1/en not_active Abandoned
- 2004-03-08 DE DE602004023183T patent/DE602004023183D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004080284A3 (en) | 2004-10-21 |
| EP1605847B1 (de) | 2009-09-16 |
| CA2530166A1 (en) | 2004-09-23 |
| WO2004080284A9 (en) | 2005-07-28 |
| WO2004080284A2 (en) | 2004-09-23 |
| DE602004023183D1 (de) | 2009-10-29 |
| US20060231107A1 (en) | 2006-10-19 |
| EP1605847A4 (de) | 2008-02-27 |
| EP1605847A2 (de) | 2005-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE442861T1 (de) | Gegen antikörper gerichtete photodynamische therapie | |
| CY1120070T1 (el) | Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους | |
| LTPA2017009I1 (lt) | Brutono tirozinkinazės inhibitoriai | |
| DK1742644T3 (da) | Terapeutisk sammensætning indeholdende mindst et pyrrolbenzodiazepin-derivat og fludarabin | |
| NO20054988D0 (no) | Preparater og metoder for behandling av cancer | |
| TNSN05300A1 (en) | Treatment with anti-vegf antibodies | |
| DK1594542T3 (da) | Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer | |
| EA201001695A1 (ru) | Применение эпотилона d для лечения заболеваний, связанных с тау-белком | |
| ATE461217T1 (de) | Glp-1-verbindungen | |
| TW200612918A (en) | Lonidamine analogs | |
| DK1558616T3 (da) | Meso-substituerede porphyriner | |
| BR0010702A (pt) | Novas quinonas como terapias de doenças | |
| NO20072543L (no) | Anti-cancer-behandling | |
| DK1276501T5 (da) | Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi | |
| EA201070195A1 (ru) | ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОПИРРОЛО [1,2-А]ПИРАЗИН-6-КАРБОКСАМИДОВ И 2,3,4,5-ТЕТРАГИДРОПИРРОЛО [1,2-a][1,4]-ДИАЗЕПИН-7-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| NO20055390D0 (no) | Thorium-227 for anvendelse i radioterapi pa mykvevssykdommer | |
| DK1596879T3 (da) | Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis | |
| BR0308976A (pt) | Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia | |
| DK1708693T3 (da) | Farmaceutiske sammensætninger indeholdende platinkomplekser med sekundære xanthater og terapeutiske anvendelser deraf | |
| ITMI20041923A1 (it) | Sorgente luminosa per terapia fotodinamica con caratteristiche migliorate per l'implementazione dei protocolli terapeutici | |
| TW200509922A (en) | Methods of therapeutic treatment using amounts of retinoid components | |
| CY1117275T1 (el) | Μεθοδοι θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος enanti-erbb-μεϊτανσινοειδους |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |